T. Brian Crum's most recent trade in Lexicon Pharmaceuticals Inc was a trade of 69,387 Common Stock done . Disclosure was reported to the exchange on Feb. 28, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 69,387 | 306,437 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 69,387 | 138,773 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.67 per share. | 28 Feb 2025 | 45,622 | 260,815 (0%) | 0% | 0.7 | 30,567 | Common Stock |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 33,456 | 33,457 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 33,456 | 237,050 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 26,097 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2025 | 26,097 | 203,594 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 765,730 | 765,730 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 510,490 | 510,490 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | T. Crum Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,457 | 203,101 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Crum T. Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 33,457 | 66,913 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | T. Brian Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 26,096 | 26,097 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Crum Brian T. | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 26,096 | 169,644 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Crum T. Brian | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.62 per share. | 28 Feb 2024 | 25,604 | 177,497 (0%) | 0% | 2.6 | 67,082 | Common Stock |
| Lexicon Pharmaceuticals Inc | Crum T. Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,750 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Crum T. Brian | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2024 | 8,750 | 143,548 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Crum Brian T. | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 208,160 | 208,160 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | T. Crum Brian | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Feb 2024 | 208,160 | 208,160 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 26,097 | 52,193 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 26,097 | 155,335 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 21,030 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 21,030 | 120,488 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.17 per share. | 28 Feb 2023 | 20,537 | 134,798 (0%) | 0% | 2.2 | 44,565 | Common Stock |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,750 | 8,750 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2023 | 8,750 | 129,238 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 301,100 | 301,100 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 100,370 | 100,370 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 21,030 | 105,767 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 21,030 | 21,030 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 2.85 per share. | 28 Feb 2022 | 15,059 | 99,458 (0%) | 0% | 2.8 | 42,918 | Common Stock |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,100 | 84,737 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 11,100 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,750 | 114,517 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2022 | 8,750 | 17,500 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 234,870 | 234,870 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | SVP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2022 | 78,290 | 78,290 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 21,030 | 42,060 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 21,030 | 88,497 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Payment of exercise price or tax liability using portion of securities received from the company at price $ 7.19 per share. | 28 Feb 2021 | 14,860 | 73,637 (0%) | 0% | 7.2 | 106,843 | Common Stock |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 11,100 | 11,100 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 11,100 | 67,467 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,118 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 5,118 | 56,367 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,517 | 0 | - | - | Restricted Stock Units | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Feb 2021 | 1,517 | 51,249 (0%) | 0% | - | Common Stock | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 78,760 | 78,760 | - | - | Stock Option (Right to Buy) | |
| Lexicon Pharmaceuticals Inc | Brian T. Crum | VP, General Counsel & Secr. | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2021 | 26,250 | 26,250 | - | - | Restricted Stock Units |